专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08501981B2 CXCR2 inhibitors 有权
标题翻译： CXCR2抑制剂
公开(公告)号：US08501981B2
公开(公告)日：2013-08-06
申请号：US12337040
申请日：2008-12-17
申请人： Stephanie Hachtel , Juergen Dedio , Elisabeth DeFossa , Sven Grueneberg , Holger Heitsch , William Bock , Charlie Chen , Raymond Kosley , Chung-Yi Kung , Marcel Patek , Rosy Sher , Stephen Shimshock , Aleksandra Weichsel
发明人： Stephanie Hachtel , Juergen Dedio , Elisabeth DeFossa , Sven Grueneberg , Holger Heitsch , William Bock , Charlie Chen , Raymond Kosley , Chung-Yi Kung , Marcel Patek , Rosy Sher , Stephen Shimshock , Aleksandra Weichsel
IPC分类号： C07C229/00 , C07C69/76 , C07C61/00 , A01N37/12
CPC分类号： C07D333/16 , C07C233/83 , C07C235/66 , C07C237/48 , C07C311/29 , C07C2601/04 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07D213/65 , C07D215/26 , C07D233/60 , C07D295/088 , C07D307/24 , C07D333/64
摘要： The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及其中R 1，R 2，X，A，B，Z和Y 1至Y 4具有权利要求中所示含义的式I化合物和/或其药学上可接受的盐和/或前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

2. 发明申请

US20080090854A1 CXCR2 INHIBITORS 有权
标题翻译： CXCR2抑制剂
公开(公告)号：US20080090854A1
公开(公告)日：2008-04-17
申请号：US11771958
申请日：2007-06-29
申请人： Stephanie HACHTEL , Juergen DEDIO , Holger HEITSCH , Werngard Czechtizky , Sven Grueneberg , Stephen Shimshock , Raymond Kosley , Carolina Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
发明人： Stephanie HACHTEL , Juergen DEDIO , Holger HEITSCH , Werngard Czechtizky , Sven Grueneberg , Stephen Shimshock , Raymond Kosley , Carolina Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
IPC分类号： A61K31/195 , A61K31/381 , A61K31/4245 , A61K31/428 , A61K31/44 , A61K31/4436 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/505 , A61P11/00 , A61P17/00 , A61P25/00 , A61P29/00 , A61P9/00 , C07C235/66 , C07D211/60 , C07D213/56 , C07D215/14 , C07D239/36 , C07D271/00 , C07D277/64 , C07D333/50 , C07D409/12
CPC分类号： C07D213/68 , C07D207/325 , C07D213/30 , C07D213/65 , C07D213/69 , C07D215/14 , C07D217/26 , C07D231/12 , C07D233/64 , C07D249/06 , C07D249/08 , C07D249/18 , C07D261/08 , C07D263/32 , C07D271/12 , C07D277/24 , C07D277/64 , C07D307/42 , C07D317/54 , C07D319/20 , C07D333/56 , C07D333/70 , C07D409/12 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及式I化合物：其中R1，R2，X，A，B，D和Y1至Y4具有权利要求中所示的含义，和/或其药学上可接受的盐和/或前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

3. 发明授权

US08283479B2 CXCR2 inhibitors 有权
标题翻译： CXCR2抑制剂
公开(公告)号：US08283479B2
公开(公告)日：2012-10-09
申请号：US13079522
申请日：2011-04-04
申请人： Stephanie Hachtel , Juergen Dedio , Holger Heitsch , Werngard Czechtizky , Sven Grueneberg , Stephen J. Shimshock , Raymond W. Kosley, Jr. , Carolina L. Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
发明人： Stephanie Hachtel , Juergen Dedio , Holger Heitsch , Werngard Czechtizky , Sven Grueneberg , Stephen J. Shimshock , Raymond W. Kosley, Jr. , Carolina L. Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
IPC分类号： C07D333/66 , C07D409/12 , A61K31/44
CPC分类号： C07D213/68 , C07D207/325 , C07D213/30 , C07D213/65 , C07D213/69 , C07D215/14 , C07D217/26 , C07D231/12 , C07D233/64 , C07D249/06 , C07D249/08 , C07D249/18 , C07D261/08 , C07D263/32 , C07D271/12 , C07D277/24 , C07D277/64 , C07D307/42 , C07D317/54 , C07D319/20 , C07D333/56 , C07D333/70 , C07D409/12 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及式I化合物：其中R1，R2，X，A，B，D和Y1至Y4具有权利要求中所示的含义，和/或其药学上可接受的盐和/或前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

4. 发明授权

US07919628B2 CXCR2 inhibitors 有权
标题翻译： CXCR2抑制剂
公开(公告)号：US07919628B2
公开(公告)日：2011-04-05
申请号：US11771958
申请日：2007-06-29
申请人： Stephanie Hachtel , Juergen Dedio , Holger Heitsch , Werngard Czechtizky , Sven Grueneberg , Stephen J. Shimshock , Raymond W. Kosley, Jr. , Carolina L. Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
发明人： Stephanie Hachtel , Juergen Dedio , Holger Heitsch , Werngard Czechtizky , Sven Grueneberg , Stephen J. Shimshock , Raymond W. Kosley, Jr. , Carolina L. Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
IPC分类号： C07D277/64 , A61K31/426
CPC分类号： C07D213/68 , C07D207/325 , C07D213/30 , C07D213/65 , C07D213/69 , C07D215/14 , C07D217/26 , C07D231/12 , C07D233/64 , C07D249/06 , C07D249/08 , C07D249/18 , C07D261/08 , C07D263/32 , C07D271/12 , C07D277/24 , C07D277/64 , C07D307/42 , C07D317/54 , C07D319/20 , C07D333/56 , C07D333/70 , C07D409/12 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及式I化合物：其中R1，R2，X，A，B，D和Y1至Y4具有权利要求中所示的含义，和/或其药学上可接受的盐和/或前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

5. 发明申请

US20110184177A1 CXCR2 INHIBITORS 有权
标题翻译： CXCR2抑制剂
公开(公告)号：US20110184177A1
公开(公告)日：2011-07-28
申请号：US13079522
申请日：2011-04-04
申请人： Stephanie Hachtel , Juergen Dedio , Holger Heitsch , Werngard Czechtizky , Sven Grueneberg , Stephen J. Shimshock , Raymond W. Kosley, JR. , Carolina L. Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
发明人： Stephanie Hachtel , Juergen Dedio , Holger Heitsch , Werngard Czechtizky , Sven Grueneberg , Stephen J. Shimshock , Raymond W. Kosley, JR. , Carolina L. Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
IPC分类号： C07D333/70 , C07D417/12 , C07D495/04 , C07D409/12
CPC分类号： C07D213/68 , C07D207/325 , C07D213/30 , C07D213/65 , C07D213/69 , C07D215/14 , C07D217/26 , C07D231/12 , C07D233/64 , C07D249/06 , C07D249/08 , C07D249/18 , C07D261/08 , C07D263/32 , C07D271/12 , C07D277/24 , C07D277/64 , C07D307/42 , C07D317/54 , C07D319/20 , C07D333/56 , C07D333/70 , C07D409/12 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
摘要翻译：本发明涉及式I化合物：其中R1，R2，X，A，B，D和Y1至Y4具有权利要求中所示的含义，和/或其药学上可接受的盐和/或前药。由于其作为趋化因子受体的抑制剂的特性，特别是作为CXCR2抑制剂，式I化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。

6. 发明授权

US07777042B2 N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof 有权
标题翻译： N-磺酰基吡啶酸衍生物FKBP结合组合物及其药物用途
公开(公告)号：US07777042B2
公开(公告)日：2010-08-17
申请号：US11567421
申请日：2006-12-06
申请人： Raymond W. Kosley, Jr. , Bruce Baron , Patrick Jimonet , John G. Jurcak , Stephen J. Shimshock , Xu-Yang Zhao , Rosy Sher , Paul J. Mueller , Jennifer Beall , Matthieu Barrague , Joseph W. Guiles
发明人： Raymond W. Kosley, Jr. , Bruce Baron , Patrick Jimonet , John G. Jurcak , Stephen J. Shimshock , Xu-Yang Zhao , Rosy Sher , Paul J. Mueller , Jennifer Beall , Matthieu Barrague , Joseph W. Guiles
IPC分类号： A61K31/535 , C07D211/30
CPC分类号： C07D401/12 , C07D211/96 , C07D405/12 , C07D409/14
摘要： A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R1, R2, R3 and X are as defined herein.
摘要翻译：公开了一种用于结合FKBP蛋白质的组合物以及治疗与神经元变性相关的病症的方法，其中所述组合物包含式I化合物，其中R 1，R 2，R 3和X如本文所定义。

7. 发明授权

US08207181B2 Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof 有权
标题翻译：取代的二氢，三氢和四氢环烷基唑并吡咯酮，其制备和应用
公开(公告)号：US08207181B2
公开(公告)日：2012-06-26
申请号：US12875700
申请日：2010-09-03
申请人： Raymond Walter Kosley, Jr. , Rosy Sher
发明人： Raymond Walter Kosley, Jr. , Rosy Sher
IPC分类号： A01N43/54 , A61K31/505 , C07D239/00
CPC分类号： C07D498/04
摘要： The present disclosure relates to a series of 2-substituted-di- tri or tetra-hydro-8H-cyclopentaoxazolo[3,2-a]pyrimidin-8-ones and 2-substituted-di-, tetra-, or hexa-hydro-cyclohexaoxazolo[3,2-a]pyrimidin-9-ones of formula (I): wherein p, n, A, B, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.
摘要翻译：本公开涉及一系列2-取代二 - 二或四氢-8H-环五唑并[3,2-a]嘧啶-8-酮和2-取代二 - ，四 - 或六氢 - - 环己氧氮杂并[3,2-a]嘧啶-9-酮其中p，n，A，B，X，Y，R1，R2，R3，R4，R5，R6，R7和R8分别为本文定义。本发明还涉及制备这些化合物的方法，包括新型中间体。本发明的化合物是代谢型谷氨酸受体（mGluR），特别是mGluR2受体的调节剂。因此，本发明的化合物可用作药物，特别是用于治疗和/或预防各种中枢神经系统疾病（CNS），包括但不限于急性和慢性神经变性疾病，精神病，抽搐，焦虑，抑郁症，偏头痛，疼痛，睡眠障碍和呕吐。

8. 发明申请

US20080139556A1 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF 有权
标题翻译： FKBP结合组合物及其药物用途
公开(公告)号：US20080139556A1
公开(公告)日：2008-06-12
申请号：US11567421
申请日：2006-12-06
申请人： Raymond W. KOSLEY , Bruce Baron , Patrick Jimonet , John G. Jurcak , Stephen J. Shimshock , Xu-yang Zhao , Rosy Sher , Paul J. Mueller , Jennifer Beall , Matthieu Barrague , Joseph W. Guiles
发明人： Raymond W. KOSLEY , Bruce Baron , Patrick Jimonet , John G. Jurcak , Stephen J. Shimshock , Xu-yang Zhao , Rosy Sher , Paul J. Mueller , Jennifer Beall , Matthieu Barrague , Joseph W. Guiles
IPC分类号： A61K31/5377 , C07D221/00 , C07D295/00 , A61K31/445 , A61P25/00 , A61K31/496 , A61K31/453 , A61K31/454
CPC分类号： C07D401/12 , C07D211/96 , C07D405/12 , C07D409/14
摘要： A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R1, R2, R3 and X are as defined herein.
摘要翻译：公开了一种用于结合FKBP蛋白的组合物，以及治疗与神经元变性相关的病症的方法，其中所述组合物包含式I化合物，其中R 1，R 2，R 2 R 3和X如本文所定义。

9. 发明授权

US08642603B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof 有权
标题翻译：取代的二氢和四氢恶唑啉嘧啶酮，其制备和应用
公开(公告)号：US08642603B2
公开(公告)日：2014-02-04
申请号：US12554129
申请日：2009-09-04
申请人： Bin Cao , Vieroslava Gurunian , Sathapana Kongsamut , Raymond W. Kosley, Jr. , Rosy Sher , Ryan E. Hartung
发明人： Bin Cao , Vieroslava Gurunian , Sathapana Kongsamut , Raymond W. Kosley, Jr. , Rosy Sher , Ryan E. Hartung
IPC分类号： C07D491/04 , A61K31/519 , A61P25/28 , A61P25/22 , A61P25/18 , A61P25/06 , A61P25/02
CPC分类号： C07D498/04
摘要： The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.
摘要翻译：本发明涉及一系列取代的二氢和四氢恶唑啉嘧啶酮，特别涉及一系列2-取代-2,3-二氢 - 恶唑并[3,2-a]嘧啶-7-酮和2-取代-2,2-二氧杂唑并[ （I）的3,5,6-四氢恶唑并[3,2-a]嘧啶-7-酮：其中p，n，X，Y，R1，R2，R3，R4，R5，R6， R7和R8如本文所定义。本发明还涉及制备这些化合物的方法，包括新型中间体。本发明的化合物是代谢型谷氨酸受体（mGluR），特别是mGluR2受体的调节剂。因此，本发明的化合物可用作药物，特别是用于治疗和/或预防各种中枢神经系统疾病（CNS），包括但不限于急性和慢性神经变性疾病，精神病，抽搐，焦虑，抑郁症，偏头痛，疼痛，睡眠障碍和呕吐。

10. 发明授权

US09051331B2 Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof 有权
标题翻译：取代的二氢苯并环烷氧基甲基恶唑啉嘧啶酮，其制备和应用
公开(公告)号：US09051331B2
公开(公告)日：2015-06-09
申请号：US13410723
申请日：2012-03-02
申请人： Rosy Sher , Raymond Walter Kosley, Jr.
发明人： Rosy Sher , Raymond Walter Kosley, Jr.
IPC分类号： C07D491/048 , C07D498/04 , A61K31/519 , A61K31/522
CPC分类号： C07D498/04 , A61K31/519 , A61K31/522
摘要： The present invention relates to a series of substituted dihydro benzocycloalkyl-oxymethyl oxazolopyrimidinones of formula (I): Wherein n, R1, R2, R3, R4, R5 and R6 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, cognition deficit disorders, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.
摘要翻译：本发明涉及式（I）的一系列取代的二氢苯并环烷基 - 氧甲基恶唑啉嘧啶酮：其中n，R1，R2，R3，R4，R5和R6如本文所定义。本发明还涉及制备这些化合物的方法，包括新型中间体。本发明的化合物是代谢型谷氨酸受体（mGluR），特别是mGluR2受体的调节剂。因此，本发明的化合物可用作药剂，特别是用于治疗和/或预防各种中枢神经系统疾病（CNS），包括但不限于急性和慢性神经变性疾病，精神病，认知缺陷障碍，惊厥，焦虑，抑郁，偏头痛，疼痛，睡眠障碍和呕吐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式